Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

LXRX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Leerink Partners reaffirmed a “market perform” rating and set a $1.00 target price (down from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Leerink Partnrs lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Finally, Piper Sandler decreased their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Trading Down 5.5 %

LXRX opened at $0.42 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The stock’s 50 day moving average price is $0.57 and its 200-day moving average price is $0.95. Lexicon Pharmaceuticals has a one year low of $0.28 and a one year high of $2.45. The stock has a market cap of $103.15 million, a price-to-earnings ratio of -0.56 and a beta of 1.02.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. On average, equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Bayesian Capital Management LP purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth $31,000. RPO LLC bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $33,000. Renaissance Technologies LLC bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $38,000. Arizona State Retirement System lifted its stake in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,136 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 24,615 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.